These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

400 related articles for article (PubMed ID: 31731005)

  • 41. Bile acid modulators for the treatment of nonalcoholic steatohepatitis (NASH).
    Fiorucci S; Biagioli M; Sepe V; Zampella A; Distrutti E
    Expert Opin Investig Drugs; 2020 Jun; 29(6):623-632. PubMed ID: 32552182
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Emerging Treatments for Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis.
    Gawrieh S; Chalasani N
    Clin Liver Dis; 2018 Feb; 22(1):189-199. PubMed ID: 29128056
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Aldafermin in patients with non-alcoholic steatohepatitis (ALPINE 2/3): a randomised, double-blind, placebo-controlled, phase 2b trial.
    Harrison SA; Abdelmalek MF; Neff G; Gunn N; Guy CD; Alkhouri N; Bashir MR; Freilich B; Kohli A; Khazanchi A; Sheikh MY; Leibowitz M; Rinella ME; Siddiqui MS; Kipnes M; Moussa SE; Younes ZH; Bansal M; Baum SJ; Borg B; Ruane PJ; Thuluvath PJ; Gottwald M; Khan M; Chen C; Melchor-Khan L; Chang W; DePaoli AM; Ling L; Lieu HD
    Lancet Gastroenterol Hepatol; 2022 Jul; 7(7):603-616. PubMed ID: 35325622
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Current status and challenges in the drug treatment for fibrotic nonalcoholic steatohepatitis.
    Shi YW; Fan JG
    Acta Pharmacol Sin; 2022 May; 43(5):1191-1199. PubMed ID: 34907360
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Combination Therapies Including Cilofexor and Firsocostat for Bridging Fibrosis and Cirrhosis Attributable to NASH.
    Loomba R; Noureddin M; Kowdley KV; Kohli A; Sheikh A; Neff G; Bhandari BR; Gunn N; Caldwell SH; Goodman Z; Wapinski I; Resnick M; Beck AH; Ding D; Jia C; Chuang JC; Huss RS; Chung C; Subramanian GM; Myers RP; Patel K; Borg BB; Ghalib R; Kabler H; Poulos J; Younes Z; Elkhashab M; Hassanein T; Iyer R; Ruane P; Shiffman ML; Strasser S; Wong VW; Alkhouri N;
    Hepatology; 2021 Feb; 73(2):625-643. PubMed ID: 33169409
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pegbelfermin in Patients With Nonalcoholic Steatohepatitis and Compensated Cirrhosis (FALCON 2): A Randomized Phase 2b Study.
    Abdelmalek MF; Sanyal AJ; Nakajima A; Neuschwander-Tetri BA; Goodman ZD; Lawitz EJ; Harrison SA; Jacobson IM; Imajo K; Gunn N; Halegoua-DeMarzio D; Akahane T; Boone B; Yamaguchi M; Chatterjee A; Tirucherai GS; Shevell DE; Du S; Charles ED; Loomba R
    Clin Gastroenterol Hepatol; 2024 Jan; 22(1):113-123.e9. PubMed ID: 37088458
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Nonalcoholic Steatohepatitis (NASH) and Hepatic Fibrosis: Emerging Therapies.
    Wattacheril J; Issa D; Sanyal A
    Annu Rev Pharmacol Toxicol; 2018 Jan; 58():649-662. PubMed ID: 29058997
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Emerging therapies for the treatment of nonalcoholic steatohepatitis: A systematic review.
    Guirguis E; Grace Y; Bolson A; DellaVecchia MJ; Ruble M
    Pharmacotherapy; 2021 Mar; 41(3):315-328. PubMed ID: 33278029
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A phase 2, adaptive randomized, double-blind, placebo-controlled, multicenter, 52-week study of HM15211 in patients with biopsy-confirmed non-alcoholic steatohepatitis - Study design and rationale of HM-TRIA-201 study.
    Abdelmalek MF; Suzuki A; Sanchez W; Lawitz E; Filozof C; Cho H; Baek E; Choi J; Baek S
    Contemp Clin Trials; 2023 Jul; 130():107176. PubMed ID: 37028504
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Improvement in Hepatic Fibrosis Biomarkers Associated With Chemokine Receptor Inactivation Through Mutation or Therapeutic Blockade.
    Sherman KE; Abdel-Hameed E; Rouster SD; Shata MTM; Blackard JT; Safaie P; Kroner B; Preiss L; Horn PS; Kottilil S
    Clin Infect Dis; 2019 May; 68(11):1911-1918. PubMed ID: 30239650
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Evolving Role for Pharmacotherapy in NAFLD/NASH.
    Attia SL; Softic S; Mouzaki M
    Clin Transl Sci; 2021 Jan; 14(1):11-19. PubMed ID: 32583961
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A structurally optimized FXR agonist, MET409, reduced liver fat content over 12 weeks in patients with non-alcoholic steatohepatitis.
    Harrison SA; Bashir MR; Lee KJ; Shim-Lopez J; Lee J; Wagner B; Smith ND; Chen HC; Lawitz EJ
    J Hepatol; 2021 Jul; 75(1):25-33. PubMed ID: 33581174
    [TBL] [Abstract][Full Text] [Related]  

  • 53. CONTROL: A randomized phase 2 study of obeticholic acid and atorvastatin on lipoproteins in nonalcoholic steatohepatitis patients.
    Pockros PJ; Fuchs M; Freilich B; Schiff E; Kohli A; Lawitz EJ; Hellstern PA; Owens-Grillo J; Van Biene C; Shringarpure R; MacConell L; Shapiro D; Cohen DE
    Liver Int; 2019 Nov; 39(11):2082-2093. PubMed ID: 31402538
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Simtuzumab Is Ineffective for Patients With Bridging Fibrosis or Compensated Cirrhosis Caused by Nonalcoholic Steatohepatitis.
    Harrison SA; Abdelmalek MF; Caldwell S; Shiffman ML; Diehl AM; Ghalib R; Lawitz EJ; Rockey DC; Schall RA; Jia C; McColgan BJ; McHutchison JG; Subramanian GM; Myers RP; Younossi Z; Ratziu V; Muir AJ; Afdhal NH; Goodman Z; Bosch J; Sanyal AJ;
    Gastroenterology; 2018 Oct; 155(4):1140-1153. PubMed ID: 29990488
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Hammerhead-type FXR agonists induce an enhancer RNA
    Chen J; Wang R; Xiong F; Sun H; Kemper B; Li W; Kemper J
    Elife; 2024 Apr; 13():. PubMed ID: 38619504
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Haptoglobin Genotype and Vitamin E Versus Placebo for the Treatment of Nondiabetic Patients with Nonalcoholic Steatohepatitis in China: A Multicenter, Randomized, Placebo-Controlled Trial Design.
    Zang S; Chen J; Song Y; Bai L; Chen J; Chi X; He F; Sheng H; Wang J; Xie S; Xie W; Yang Y; Zhang J; Zheng M; Zou Z; Wang B; Shi J;
    Adv Ther; 2018 Feb; 35(2):218-231. PubMed ID: 29411270
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Current and new pharmacotherapy options for non-alcoholic steatohepatitis.
    Sumida Y; Yoneda M; Ogawa Y; Yoneda M; Okanoue T; Nakajima A
    Expert Opin Pharmacother; 2020 Jun; 21(8):953-967. PubMed ID: 32237916
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pharmacological Inhibition of CCR2/5 Signaling Prevents and Reverses Alcohol-Induced Liver Damage, Steatosis, and Inflammation in Mice.
    Ambade A; Lowe P; Kodys K; Catalano D; Gyongyosi B; Cho Y; Iracheta-Vellve A; Adejumo A; Saha B; Calenda C; Mehta J; Lefebvre E; Vig P; Szabo G
    Hepatology; 2019 Mar; 69(3):1105-1121. PubMed ID: 30179264
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Farnesoid X nuclear receptor agonists for the treatment of nonalcoholic steatohepatitis.
    Venetsanaki V; Karabouta Z; Polyzos SA
    Eur J Pharmacol; 2019 Nov; 863():172661. PubMed ID: 31536725
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Non-alcoholic fatty liver disease and steatohepatitis: State of the art on effective therapeutics based on the gold standard method for diagnosis.
    Mahjoubin-Tehran M; De Vincentis A; Mikhailidis DP; Atkin SL; Mantzoros CS; Jamialahmadi T; Sahebkar A
    Mol Metab; 2021 Aug; 50():101049. PubMed ID: 32673798
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.